TY  - JOUR
AU  - Gathe, Joseph
AU  - Rubio, Rafael
AU  - Berstein, Barry
PY  - 2009
DO  - 10.1097/QAI.0b013e31819c2937
SN  - 1525-4135
UR  - https://hdl.handle.net/20.500.14352/107062
T2  - Journal of Acquirired Immune Deficiency Syndrome
AB  - Background: Lopinavir/ritonavir (LPV/r)-dosed twice daily has demonstrated durable efficacy in antiretroviral-naive and protease inhibitor (PI) -experienced patients. Study M05-730 compared LPV/r tablets dosed once daily vs. twice daily in...
LA  - eng
M2  - 474
PB  - Lippincott Williams & Wilkins
KW  - Lopinavir/ritonavir
KW  - VIH
KW  - Antiretrovirales
TI  - A once-daily lopinavir/ritonavir- based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks
TY  - journal article
VL  - 50
ER  -